Rintaro Hashizume

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6880610/publications.pdf

Version: 2024-02-01

83	4,536	136885 32	106281 65
papers	citations	h-index	g-index

84	84	84	6999
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation. Journal of Biological Chemistry, 2001, 276, 14537-14540.	1.6	576
2	The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes and Development, 2013, 27, 985-990.	2.7	570
3	Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine, 2014, 20, 1394-1396.	15.2	411
4	Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nature Medicine, 2017, 23, 493-500.	15.2	332
5	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	0.6	184
6	Targeted Therapy for BRAFV600E Malignant Astrocytoma. Clinical Cancer Research, 2011, 17, 7595-7604.	3.2	143
7	New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro-Oncology, 2008, 10, 112-120.	0.6	126
8	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. Nature Medicine, 2018, 24, 758-769.	15.2	125
9	Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG. Molecular Cancer Research, 2017, 15, 1243-1254.	1.5	120
10	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene, 2000, 19, 4864-4875.	2.6	106
11	Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology, 2014, 16, 352-360.	0.6	102
12	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	0.6	92
13	Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy. Cell, 2018, 175, 766-779.e17.	13.5	86
14	Cooperative interactions of BRAF ^{V600E} kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8710-8715.	3.3	77
15	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nature Neuroscience, 2015, 18, 1236-1246.	7.1	74
16	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro-Oncology, 2016, 18, now106.	0.6	73
17	Mutations in chromatin machinery and pediatric high-grade glioma. Science Advances, 2016, 2, e1501354.	4.7	69
18	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes and Development, 2012, 26, 1780-1796.	2.7	68

#	Article	IF	Citations
19	Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. Journal of Neuro-Oncology, 2012, 110, 305-313.	1.4	66
20	Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro-Oncology, 2013, 15, 83-90.	0.6	59
21	A human brainstem glioma xenograft model enabled for bioluminescence imaging. Journal of Neuro-Oncology, 2010, 96, 151-159.	1.4	56
22	A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism. Genes and Development, 2017, 31, 2056-2066.	2.7	55
23	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2019, 25, 5572-5583.	3.2	52
24	An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. Journal of Neuro-Oncology, 2012, 108, 29-35.	1.4	51
25	Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. Frontiers in Oncology, 2015, 5, 148.	1.3	50
26	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathologica Communications, 2018, 6, 80.	2.4	50
27	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332.	3.2	44
28	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Clinical Cancer Research, 2016, 22, 5312-5321.	3.2	39
29	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Reports, 2020, 33, 108286.	2.9	39
30	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2021, 27, 1766-1777.	3.2	38
31	Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells. Molecular Cancer Therapeutics, 2010, 9, 2131-2141.	1.9	37
32	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. Epigenetics, 2017, 12, 353-369.	1.3	36
33	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. Neurologia Medico-Chirurgica, 2017, 57, 331-342.	1.0	36
34	Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Research, 2015, 75, 5355-5366.	0.4	33
35	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Reports, 2017, 18, 3167-3177.	2.9	32
36	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology, 2016, 126, 385-393.	1.4	31

#	Article	IF	Citations
37	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657.	3.2	30
38	Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Journal of Neuro-Oncology, 2017, 131, 495-505.	1.4	29
39	Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. Oncotarget, 2017, 8, 111190-111212.	0.8	26
40	Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-Oncology, 2010, 12, 366-376.	0.6	23
41	Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models. Journal of Visualized Experiments, 2010, , .	0.2	22
42	Convection-enhanced delivery of targeted quantum dotâ€“immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine, 2013, 8, 1913-1925.	1.7	22
43	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. Journal of Neuro-Oncology, 2018, 136, 475-484.	1.4	22
44	Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. Journal of Translational Medicine, 2014, 12, 345.	1.8	21
45	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Frontiers in Oncology, 2019, 9, 1568.	1.3	18
46	Imidazoquinolines: Recent Developments in Anticancer Activity. Mini-Reviews in Medicinal Chemistry, 2016, 16, 309-322.	1.1	17
47	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Research, 2019, 79, 4026-4041.	0.4	16
48	A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cellâ€ofâ€origin dependent effects of <scp>H3K27M</scp>. Glia, 2022, 70, 1681-1698.	2.5	15
49	Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging. Contrast Media and Molecular Imaging, 2018, 2018, 1-6.	0.4	12
50	Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma. Neuro-Oncology, 2021, 23, 1348-1359.	0.6	12
51	Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas. Current Neuropharmacology, 2016, 15, 98-103.	1.4	12
52	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma. Neurosurgery, 2020, 87, E680-E688.	0.6	11
53	A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. Acta Neuropathologica Communications, 2022, 10, 47.	2.4	11
54	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. Molecular Cancer Therapeutics, 2022, 21, 715-726.	1.9	11

#	Article	IF	Citations
55	Potent Antineoplastic Effects of Combined PI3KÎ±â€“MNK Inhibition in Medulloblastoma. Molecular Cancer Research, 2019, 17, 1305-1315.	1.5	10
56	The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neuro-Oncology Advances, 2021, 3, vdab085.	0.4	10
57	Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas. Neoplasia, 2019, 21, 505-515.	2.3	9
58	Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics, 2017, 14, 385-392.	2.1	8
59	ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. Neurosurgery, 2020, 86, 742-751.	0.6	8
60	Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma. Journal of Visualized Experiments, 2016, , e53287.	0.2	7
61	Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery. Current Opinion in Molecular Therapeutics, 2010, 12, 168-75.	2.8	6
62	IMMU-24. IMMUNOTHERAPEUTIC NANOTECHNOLOGY TARGETING IDO1 FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i103-i103.	0.6	2
63	IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2019, 21, ii92-ii93.	0.6	2
64	Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors. Neuro-Oncology Advances, 2021, 3, vdab137.	0.4	2
65	NIMG-73. RADIOMICS OF GLIOBLASTOMA FOR PREDICTING MGMT PROMOTOR METHYLATION STATUS AND PROGNOSIS. Neuro-Oncology, 2018, 20, vi192-vi192.	0.6	1
66	DIPG-33. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. Neuro-Oncology, 2018, 20, i55-i55.	0.6	1
67	LSD1 inhibition in pHGG: the key to unleashing immunotherapy?. Neuro-Oncology, 2020, 22, 1237-1238.	0.6	1
68	A CASE OF DUODENAL AND JEJUNALCOLIC FISTULAS DUE TO OF THE TRANSVERS COLON. The Journal of the Japanese Practical Surgeon Society, 1993, 54, 725-729.	0.0	1
69	IMMU-46. AÂsiRNA APPROACH FOR TARGETING IMMUNOSUPPRESSIVE IDO1 IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2017, 19, vi122-vi123.	0.6	0
70	DIPG-36. NOVEL THERAPEUTIC APPROACHES USING NANOLIPOSMAL SN-38 FOR THE TREATMENT OF HUMAN BRAINSTEM GLIOMA. Neuro-Oncology, 2017, 19, iv13-iv13.	0.6	0
71	SCDT-20. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. Neuro-Oncology, 2017, 19, vi269-vi269.	0.6	0
72	DIPG-28. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG. Neuro-Oncology, 2017, 19, iv10-iv11.	0.6	0

#	Article	IF	Citations
73	PDTM-10. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, vi205-vi206.	0.6	0
74	DIPG-63. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG. Neuro-Oncology, 2018, 20, i61-i62.	0.6	0
75	EPEN-30. HISTONE H3 LYSINE 4 TRIMETHYLATION IS A POTENTIAL TARGET TO IMPROVE CHEMOTHERAPEUTIC EFFICACY FOR PEDIATRIC PRIMARY EPENDYMOMAS. Neuro-Oncology, 2018, 20, i79-i79.	0.6	0
76	PDTM-42. TARGETED INHIBITION OF BET BROMODOMAIN AND JMJD3 PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, vi212-vi213.	0.6	0
77	DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i49-i50.	0.6	0
78	DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES. Neuro-Oncology, 2018, 20, i49-i49.	0.6	0
79	DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG. Neuro-Oncology, 2019, 21, ii70-ii70.	0.6	0
80	HGG-10. HISTONE H3G34V MUTATION IS SUFFICIENT TO DRIVE DISTINCT GENOMIC H3K36 METHYLATION PATTERNS IN PEDIATRIC GLIOMA. Neuro-Oncology, 2019, 21, ii88-ii89.	0.6	0
81	HGG-26. H3G34V MUTATION AFFECTS GENOMIC H3K36 METHYLATION IN PEDIATRIC GLIOMA. Neuro-Oncology, 2020, 22, iii348-iii348.	0.6	0
82	DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii285-iii286.	0.6	0
83	DDRE-15. THE COMBINATION THERAPY OF PARP INHIBITOR AND TMZ IN DIFFUSE MIDLINE GLIOMA HARBORING H3 K27M-MUTANT. Neuro-Oncology, 2020, 22, ii64-ii64.	0.6	0